EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of MEI Pharma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 11^th day of February, 2021.

UBS ONCOLOGY IMPACT FUND, L.P.
By: Oncology Impact Fund (Cayman)         Management L.P., its General Partner
By: MPM Oncology Impact Management LP,
Its General Partner
By: MPM Oncology Impact Management GP LLC
Its General Partner
By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke
Title:	Managing Director
ONCOLOGY IMPACT FUND (Cayman) MANAGEMENT L.P.
By: MPM Oncology Impact Management LP,
Its General Partner
By: MPM Oncology Impact Management GP LLC
Its General Partner
By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke
Title:	Managing Director
MPM ONCOLOGY IMPACT MANAGEMENT LP
By: MPM Oncology Impact Management GP LLC
Its General Partner
By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke
Title:	Managing Director

Page 11 of 12

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC
By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke
Title:	Managing Director
By:	/s/ Ansbert Gadicke
Name:	Ansbert Gadicke

Page 12 of 12